TY  - GEN
AU  - Bartz,René
AU  - Fukuchi,Keisuke
AU  - Ohtsuka,Toshiaki
AU  - Lange,Tanja
AU  - Gruner,Katrin
AU  - Watanabe,Ichiro
AU  - Hayashi,Shinko
AU  - Oda,Yoko
AU  - Kawaida,Reimi
AU  - Komori,Hironobu
AU  - Kashimoto,Yoshinori
AU  - Wirtz,Peter
AU  - Mayer,Jan-Peter A
AU  - Redondo-Müller,Mauricio
AU  - Saito,Shuntaro
AU  - Takahashi,Mizuki
AU  - Hanzawa,Hiroyuki
AU  - Imai,Emi
AU  - Martinez,Alberto
AU  - Hanai,Masaharu
AU  - Häussinger,Dieter
AU  - Chapman,Roger W
AU  - Agatsuma,Toshinori
AU  - Bange,Johannes
AU  - Abraham,Reimar
TI  - Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity
SN  - 1538-8514
PY  - 2020///0609
KW  - Animals
KW  - Antibodies, Monoclonal
KW  - therapeutic use
KW  - Antineoplastic Agents
KW  - pharmacology
KW  - Cell Line, Tumor
KW  - Cholestyramine Resin
KW  - Female
KW  - Gene Expression Regulation
KW  - drug effects
KW  - Humans
KW  - Ileum
KW  - Liver
KW  - Mice
KW  - Mice, Inbred BALB C
KW  - NIH 3T3 Cells
KW  - Receptor, Fibroblast Growth Factor, Type 4
KW  - immunology
KW  - Signal Transduction
KW  - Sorafenib
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1535-7163.MCT-18-0048
ER  -